Key result
Use of RAAS inhibitors was associated with a lower incidence of cancer compared with other antihypertensive drugs (9.90 vs. 13.28 per 1000 person-years; HR 0.86; 95% CI 0.81-0.91).
Why the study?
Previous studies reported conflicting results on the association between renin-angiotensin-aldosterone system (RAAS) inhibitors and cancer development.
Does the use of renin-angiotensin-aldosterone system (RAAS) inhibitors reduce the occurrence of cancer in patients on antihypertensive therapy compared to other antihypertensive drugs?
Population
166,071 patients on antihypertensive therapy across seven hospitals in Korea
Comparison
RAAS inhibitors vs other antihypertensive drugs
Design
Retrospective observational cohort study
Authors
Loading...
Does not support changing antihypertensive therapy; hypothesis-generating for a potential protective association requiring RCTs.
Cohort (n=166,071)
Yes
Does the use of renin-angiotensin-aldosterone system (RAAS) inhibitors reduce the occurrence of cancer in patients on antihypertensive therapy compared to other antihypertensive drugs?
Hazard Ratio: 0.86 (95% CI 0.81–0.91)
Absolute Event Rate: 9.9% vs 13.28%
In a large Korean cohort, the use of RAAS inhibitors was associated with a significantly lower risk of incident cancer compared to other antihypertensive drugs.
Lee et al. (2022) conducted a cohort in Hypertension (n=166,071). Renin-angiotensin-aldosterone system (RAAS) inhibitors vs. Other antihypertensive drugs was evaluated on Occurrence of cancer (HR 0.86, 95% CI 0.81-0.91). Use of RAAS inhibitors was associated with a lower incidence of cancer compared with other antihypertensive drugs (9.90 vs. 13.28 per 1000 person-years; HR 0.86; 95% CI 0.81-0.91).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: